Riahizadeh, S. and Malekzadeh, R. and Agah, S. and Zendehdel, N. and Sotoudehmanesh, R. and Ebrahimi-Dariani, N. and Pourshams, A. and Vahedi, H. and Mikaeli, J. and Khatibian, M. and Massarrat, S. (2010) Sequential Metronidazole-Furazolidone or Clarithromycin-Furazolidone Compared to Clarithromycin-Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double-Blind Randomized Controlled Trial. Helicobacter, 15 (6). pp. 497-504.
Full text not available from this repository.Abstract
Background: Furazolidone is a much cheaper drug with a very low resistance against Helicobacter pylori compared to clarithromycin. We aim to evaluate safety and efficacy of a sequential furazolidone-based regimen versus clarithromycin-based therapy in H. pylori eradication for ulcer disease.Materials: Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days. All groups received omeprazole (O) (20 mg bid) and amoxicillin (A) (1 g bid). Groups OAB-M-F and OAB-C-F were also given bismuth subcitrate (B) (240 mg bid), whereas a placebo (P) was given to group OAC-P. Adverse events were scored and recorded. Two months after treatment, a C13-urea breath test was performed.Results: Three hundred and ten patients were enrolled and 92 (OAB-M-F), 95 (OAC-P), and 98 (OAB-C-F) completed the study. The intention-to-treat eradication rates were 78.5 (95 CI = 69-85), 81.1 (95 CI = 73-88), and 82 (95 CI = 74-89), and per-protocol eradication rates were 91.3 (95 CI = 83-96), 90.4 (95 CI = 82-95), and 88.7 (95 CI = 81-94), for group OAB-M-F, OAC-P, and OAB-C-F, respectively. Eradication rate differences did not reach statistical significance. The most common adverse event, bad taste, occurred in all groups, but more frequently in groups OAC-P (34) and OAB-C-F (32), than OAB-M-F (14) (p<.05). Adverse symptoms score were 0.88 ± 2.05 in group OAB-M-F, 1.15 ± 1.40 in group OAC-P, and 1.87 ± 1.62 in group OAB-C-F.Conclusion: Furazolidone can replace clarithromycin in H. pylori eradication regimens because of lack of development of resistance and very low cost. © 2010 Blackwell Publishing Ltd.
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 18 |
| Uncontrolled Keywords: | amoxicillin; bismuth citrate; carbon 13; clarithromycin; furazolidone; metronidazole; omeprazole; placebo, abdominal pain; adolescent; adult; aged; anorexia; article; bloating; clinical trial; constipation; controlled clinical trial; controlled study; diarrhea; dizziness; double blind procedure; drug fever; duodenitis; eradication therapy; female; flushing; headache; Helicobacter pylori; human; male; nausea; nonhuman; peptic ulcer; priority journal; pruritus; randomized controlled trial; rash; side effect; taste; urea breath test; vomiting; weakness; xerostomia, Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Young Adult, Helicobacter pylori |
| Subjects: | WI Digestive System |
| Depositing User: | s shekarchi shekarchi |
| Date Deposited: | 04 Oct 2021 09:43 |
| Last Modified: | 04 Oct 2021 09:43 |
| URI: | http://eprints.iums.ac.ir/id/eprint/21078 |
Actions (login required)
 |
View Item |
